The purpose of the study is to determine if the dose of Envarsus can be reduced compared to Advagraf while still maintaining effective levels of tacrolimus in the body. Participants in the study will take one of these medications orally, and their tacrolimus levels will be monitored to ensure they remain within a therapeutic range. The study will also look at whether switching to Envarsus results in fewer pills to take, fewer side effects, and more consistent medication levels in the body.

Throughout the study, researchers will also explore if certain genetic factors, like the presence of the CYP3A5*1 allele, should be considered when prescribing these medications. The trial aims to provide insights into the best dosing strategies for patients who require higher doses of tacrolimus to prevent organ rejection. The study is expected to continue until early 2026.

Participants in the study will be randomly assigned to receive either dapagliflozin or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will last for about six months, during which time the participants will continue their regular hemodialysis treatments while taking the study medication or placebo. The main focus will be on changes in the heart’s structure and function, particularly the Left Ventricular Mass, which is a measure of the heart’s size and health.

Throughout the study, various health markers will be monitored, including blood sugar levels, hormones, and heart function indicators. The goal is to see if dapagliflozin can improve heart health and overall quality of life for patients on hemodialysis. The study will provide valuable information on whether this medication can be beneficial for people with kidney and heart conditions who are undergoing hemodialysis.

The trial will test two antibiotics: amoxicillin/clavulanic acid and clindamycin. Amoxicillin/clavulanic acid is the primary treatment, but clindamycin will be used for those who cannot tolerate beta-lactam antibiotics, a common type of antibiotic. The purpose of the study is to see if taking these antibiotics can reduce the risk of infections during the first six months after starting hemodialysis with a CVC.

Participants in the study will be randomly assigned to receive either the antibiotic treatment or a placebo. The study will last for six months, during which time the health of the participants will be monitored to see if the antibiotics help prevent infections. The goal is to find out if this approach can help reduce hospitalizations due to infections in patients with end-stage kidney disease who are receiving hemodialysis.

The study involves testing different doses of RMC-035 compared to placebo to find the most effective amount of medication for protecting kidney function. During the study, participants will receive either RMC-035 or placebo through an infusion into their veins. The maximum daily dose will be 120 milligrams, and the total treatment period will last up to 2 days.

After receiving the treatment, patients will be monitored for changes in their kidney function, particularly focusing on how well their kidneys are working 90 days after surgery. The medication being tested is a biological product that contains a modified version of a protein naturally found in the body. This protein has protective properties that may help prevent kidney damage during and after heart surgery.

Participants in the study will receive everolimus, which is available in different forms such as tablets and oral solutions, under the brand name CERTICAN. The study will compare the effects of everolimus with those of a placebo. The treatment will be administered orally, and the maximum treatment period is six months. During the study, participants will have regular check-ups to monitor their kidney function and overall health.

The study aims to gather information on how well everolimus works in preventing further damage to the transplanted kidney. It will also look at changes in certain biological markers and the body’s immune response. This research is important for improving the care and outcomes for kidney transplant patients who face challenges with rejection. The findings could help guide future treatments and improve the quality of life for those affected by kidney transplant rejection.

Participants in the study will receive Grafalon® for a short period, and the effects will be monitored over time. The study will look at how the medication affects the immune system, particularly the levels of different types of blood cells, and will also track any side effects or adverse events that may occur. The study aims to find a dose that is effective in preventing complications without causing significant side effects.

Throughout the study, researchers will also observe the overall health of the participants, including their kidney function and any potential infections or other health issues that may arise after the transplant. The study will help to improve understanding of how to best use Grafalon® in kidney transplant patients to support their recovery and long-term health.

Participants in the study will receive these substances through an injection into a vein. The study will compare the results from these different substances to see if they provide similar information about kidney function. The study will involve a single treatment period, and participants will be monitored to ensure their safety throughout the process.

By comparing these methods, the study aims to find the best way to measure kidney function without using radioactive substances. This could help improve the care and treatment of people with kidney problems in the future. Participants will be randomly assigned to receive either the study substances or a placebo, and their kidney function will be measured and compared.

Participants in the study will be randomly assigned to receive either dapagliflozin or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for about 12 months, during which time the participants’ kidney function will be closely monitored. This will involve regular check-ups and tests to assess how well the kidneys are working. The main focus will be on the change in kidney function from the start of the study to the end.

In addition to monitoring kidney function, the study will also look at other health indicators, such as body weight, the ratio of certain proteins in the urine, and blood sugar levels in participants with diabetes. These additional measurements will help provide a comprehensive understanding of how dapagliflozin affects overall health in heart transplant recipients with kidney issues. The study aims to gather valuable information that could lead to improved treatment options for these patients in the future.

The purpose of the study is to determine if anakinra is more effective than prednisone in treating gout attacks in these patients. Participants in the study will receive either anakinra or prednisone, and some may receive a placebo, which looks like the real medication but does not contain any active ingredients. The study will last for a short period, during which participants will be monitored for changes in their symptoms, particularly pain levels, and any side effects they might experience.

Throughout the study, researchers will compare how quickly and effectively each treatment reduces pain and resolves the gout attacks. They will also observe any side effects, such as reactions at the injection site for anakinra or changes in blood cell counts. The study aims to provide valuable information on the best treatment options for managing gout in patients with chronic kidney disease or those who have had a kidney transplant.